CINECA IRIS Institutional Research Information System

VIVALDI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.098
AS - Asia 3.628
EU - Europa 2.812
SA - Sud America 860
AF - Africa 368
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.784
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.933
SG - Singapore 1.113
CN - Cina 1.019
IT - Italia 842
BR - Brasile 733
HK - Hong Kong 694
SE - Svezia 526
DE - Germania 342
VN - Vietnam 286
GB - Regno Unito 259
CI - Costa d'Avorio 221
BG - Bulgaria 180
RU - Federazione Russa 152
AT - Austria 113
CA - Canada 102
FI - Finlandia 102
FR - Francia 97
IN - India 84
TR - Turchia 82
KR - Corea 69
SN - Senegal 58
BD - Bangladesh 49
AR - Argentina 48
JP - Giappone 47
PL - Polonia 39
NL - Olanda 35
IQ - Iraq 32
NG - Nigeria 30
MX - Messico 29
ID - Indonesia 28
ES - Italia 27
EC - Ecuador 23
UA - Ucraina 21
PK - Pakistan 20
VE - Venezuela 19
ZA - Sudafrica 17
MA - Marocco 16
SA - Arabia Saudita 16
LT - Lituania 15
UZ - Uzbekistan 15
AU - Australia 12
RO - Romania 9
CZ - Repubblica Ceca 8
IR - Iran 8
KE - Kenya 8
PA - Panama 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
CO - Colombia 7
PY - Paraguay 7
BE - Belgio 6
CH - Svizzera 6
EG - Egitto 6
IL - Israele 6
JO - Giordania 6
MY - Malesia 6
UY - Uruguay 6
CR - Costa Rica 5
HN - Honduras 5
IE - Irlanda 5
TW - Taiwan 5
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
JM - Giamaica 4
LB - Libano 4
NZ - Nuova Zelanda 4
PH - Filippine 4
AL - Albania 3
AO - Angola 3
EE - Estonia 3
HU - Ungheria 3
KG - Kirghizistan 3
NP - Nepal 3
TN - Tunisia 3
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
BJ - Benin 2
BO - Bolivia 2
BY - Bielorussia 2
GD - Grenada 2
KH - Cambogia 2
LU - Lussemburgo 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
BZ - Belize 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
FJ - Figi 1
GE - Georgia 1
GR - Grecia 1
Totale 14.770
Salva come PNG Salva come JPEG
Città #
Ashburn 963
Hong Kong 687
Santa Clara 617
Singapore 553
Woodbridge 520
Fairfield 450
Chandler 448
Dallas 444
Houston 355
Ann Arbor 336
Shanghai 297
Abidjan 221
New York 208
Beijing 196
Wilmington 181
Seattle 180
Sofia 179
Los Angeles 167
Cambridge 165
Boardman 143
Milan 121
Princeton 117
London 112
Munich 109
Lawrence 103
Florence 101
Hefei 100
Vienna 89
Pisa 84
Ho Chi Minh City 72
Medford 71
Buffalo 64
Seoul 59
Dakar 58
Istanbul 58
Ottawa 57
Frankfurt am Main 56
Serra 50
Redondo Beach 49
San Diego 48
São Paulo 48
Hanoi 47
Düsseldorf 38
Turku 38
Des Moines 33
Nuremberg 33
Tokyo 33
Fuzhou 31
Warsaw 31
Lancaster 30
Council Bluffs 28
Lagos 28
Bremen 27
Ogden 27
Rome 27
Dearborn 26
Kent 26
Nanjing 26
Helsinki 23
Cascina 22
Baghdad 19
Hyderabad 19
Curitiba 18
Denver 17
Dong Ket 16
Hebei 16
Poplar 16
Quanzhou 16
Phoenix 15
Stockholm 15
Montreal 14
Norwalk 14
Rio de Janeiro 14
Seacroft 14
Toronto 14
Boston 13
Da Nang 13
Lappeenranta 13
Tashkent 13
Belo Horizonte 12
Changsha 12
Chicago 12
Vicopisano 12
Brasília 11
Guangzhou 11
Lucca 11
Mexico City 11
Quito 11
Shenyang 11
Boulder 10
Chennai 10
Haiphong 10
Lauterbourg 10
Manchester 10
Porto Alegre 10
Redwood City 10
The Dalles 10
Bologna 9
Genoa 9
Jacksonville 9
Totale 10.020
Salva come PNG Salva come JPEG
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 304
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 206
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 177
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 169
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 168
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 167
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 165
In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration 163
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 160
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 158
Zebrafish patient-derived xenografts identify chemo-response in pancreatic ductal adenocarcinoma patients 158
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. 156
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 154
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 154
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 153
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 147
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 147
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 146
Tumor regression grade (TRG) evaluation of 29 borderline/locally advanced pancreatic cancers (LAPCs) after neoadjuvant chemotherapy (NACT) using different pathological scores: a clinical and prognostic correlation 145
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients 142
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 139
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 139
Prognostic value of CD133 caused by mutant K-Ras and B-Raf 138
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 137
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 137
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 136
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data 135
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 134
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 133
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 131
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 130
Prognostic model for patients (PTS) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (Mfolfirinox) 129
Detailing the ultrastructure’s increase of prion protein in pancreatic adenocarcinoma 129
Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval Confluence. 125
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 123
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer 123
Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection 123
Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation 123
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 123
Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. 122
Neuroendocrine Liver Metastases 122
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 122
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 121
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort' 120
Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis 120
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 119
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 119
Prognostic value of CD133 caused by mutant K-RAS and B-RAF letter. 118
Not only chemotherapy in the second-line treatment of metastatic gastric cancer. 117
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 117
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 116
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. 116
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology 115
Resectable liver metastases from colorectal cancer: where we are now and where do we go from here? 114
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 114
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 113
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 113
Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond 109
Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions 109
FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer 108
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 108
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 107
Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples. 107
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: Is hepatic arterial infusion chemotherapy the best option? 106
Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications 106
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 103
Feasibility of BRCA1/2 testing of formalin-fixed and paraffin-embedded pancreatic tumor samples: A consecutive clinical series 103
Cholangiocarcinoma: new perspectives for new horizons 102
Robotic Versus Open Pancreatoduodenectomy With Vein Resection and Reconstruction: A Propensity Score-Matched Analysis 101
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 101
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. 99
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 99
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 99
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 98
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 97
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 96
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 95
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 95
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 94
Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer 94
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 93
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 91
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 91
Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study 90
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 90
Activity and safety of NAB-FOLFIRI and NAB-FOLFOX as first-line treatment for metastatic pancreatic cancer (NabucCO study) 90
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 89
Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres 88
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 87
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 87
About the Recently Published Paper on JAMA Oncology “Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial” 86
Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors 86
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 85
Bone metastases in biliary cancers: A multicenter retrospective survey 85
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 85
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer 84
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer 82
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients 82
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 81
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 81
Totale 12.013
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.651
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.651
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021421 0 0 0 0 26 106 19 39 55 62 30 84
2021/20221.030 14 20 17 27 171 217 30 35 67 81 90 261
2022/20231.863 186 280 154 93 177 206 15 128 450 7 141 26
2023/20241.209 73 96 144 54 161 171 154 47 37 41 90 141
2024/20254.887 28 199 90 236 443 679 371 199 502 553 622 965
2025/20263.018 503 734 632 685 464 0 0 0 0 0 0 0
Totale 15.133